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Case report
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therapeutic challenge with a review of
the literature
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Abstract

Vulvar Paget’s disease is an uncommon adenocarcinoma of the female genital tract,
occuring more often in postmenopausal Caucasian women and accounting for 1-2% of all
vulvar malignancies. A 39-year-old female patient was examined for the erythematous and
pruritic vulvar lesion, with biopsy and histological examination revealing vulvar Paget’s
disease. We did not diagnose any associated neoplasm. The patient underwent four
surgical resections for relapsed disease, varying from local excision to extended excision,
including radical vulvectomy, with esthetic coverage. The margins were involved. Due to
the extended target volumes, radiotherapy was rejected and the patient underwent a local
topical therapy with Imiquimod 5%. The patient was free of disease, with three years of
regular follow-ups. This case was challenging due to the long recurrence of the disease for
approximately 26 years and due to the therapeutics issues that occurred.
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Highlights

✓ Vulvar Paget’s disease is a therapeutic challenge for physicians due to its chronicity and
its high rate of recurrence. The management of local recurrence is associated with
mutilating surgery.

vulvar neoplasm, reconstructive surgical procedures, extramammary Paget’s disease,
Imiquimod

✓ Currently, new conservative approaches such as local cream use, laser therapy, and many
other treatments are being adopted. Imiquimod 5% cream is an alternative for
consideration in the case of invaded margins.
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Introduction
In 1876, Sir James Paget observed chronic eczematous
disease on the skin of the nipple and areola that was
associated with a breast intraductal carcinoma (1). This
entity was defined as mammary Paget’s disease. Later, in
1901, William Dubreuilh described vulvar Paget’s disease
(VPD) (2). VPD is an uncommon adenocarcinoma of the
female genital tract (3). It occurs more often in
postmenopausal Caucasian women (3) and accounts for 12% of all vulvar malignancies (3, 4).
Given its chronicity, the disease is under-diagnosed,
thus leading to a real therapeutic challenge for physicians.
Surgery remains the treatment of choice; however, many
new therapeutic approaches also seem appealing. We cite
radiotherapy, topical therapy, laser therapy, photodynamic
therapy, and radiotherapy as possibilities (5-10). Despite
these varied therapies, VPD still has high relapse rates,
ranging from 15 to 72% (5, 7, 8, 11).

Figure 1. General overview showing multiple
erythematous lesions located in mons veneris, in the
flap and in the peri-anal region (red circles).

Case report
In 1990, a 39-year-old Caucasian woman presented
with an erythematous lesion on the left hemi vulva at
another medical facility. She underwent local excision of
the lesion and the histological report revealed VPD, but the
limits and the invasion were not determined. She did not
undergo adjuvant therapy, and her case was subsequently
lost over time. Twenty-two years later (in 2012), she
presented with a new though similar lesion in the same
localization. The patient underwent mammography,
coloscopy, gastric endoscopy, and cystoscopy, and all
results were negative. She then underwent left
hemivulvectomy. The final histological examination
concluded VPD again, and the limits were free with a 2mm clearance.

Figure 2. Closeup overview of multiple
erythematous lesions located in mons veneris, in the
flap and in the peri-anal region (red arrows).
We performed punch biopsies for each suspicious
lesion, and the histological examination confirmed the
VPD recurrence. She underwent a large excision and
coverage by a V-Y flap of the inner thigh (Figures 3 and
4).

Three years later (in 2015), after the first relapse, she
presented with an erythematous lesion on the right
hemivulva and the perianal region. The inguinal areas were
free of lymph nodes. The punch biopsy with histological
examination confirmed the recurrence of VPD. She had a
totalization of the vulvectomy with excision of the perianal lesion and an advanced flap of the inner thigh. We
performed a left iliac colostomy to improve the peri-anal
scarring. The limits were not free, but the patient was lost
again. One year later (in 2016), she was referred to our
institute for an evolutive disease. The physical examination
revealed multiple erythematous lesions located in mons
veneris, in the flap and in the perianal region (Figures 1 and
2).

Figure 3. Large excision of the perineal areas, mons
veneris and the flap.
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Figure 4. Coverage by a V-Y flap of the inner thigh
Frozen section examination pointed to free limits, but
final histology exams showed involved margins. Due to the
multiple recurrences of the disease and the involved
margins, the patient was proposed for external beam
therapy. But radiotherapy was rejected due to the extent of
the target volumes. The multidisciplinary committee
indicated a topical therapy with Imiquimod 5%. The
patient underwent local therapy with imiquimod 5% twice
a week for 6 months. At the time of this publication, the
patient is 68 years old and she had no recurrence in the first
36 months after treatment.

Discussions
Vulvar Paget’s disease remains underdiagnosed due to
its rarity and its clinical presentation which mimics a
benign lesion. Wilkinson and Brown proposed a
classification that divided it into two entities: primary and
secondary disease (12). Primary Paget’s disease is an
intraepithelial adenocarcinoma that occurs in the
appendages of the epidermis or the underlying skin.
Secondary Paget’s disease is associated with underlying
noncutaneous adenocarcinoma, most frequently anorectal
adenocarcinoma, and urothelial carcinoma of the bladder
or urethra, carcinoma of the cervix, ovaries, or
endometrium (13). For this reason in our case, we did a full
workup so as to avoid underdiagnosing an underlying
adenocarcinoma.
The VPD mechanism of spreading is still under debate.
Mehta et al. supposed that a Pagetoid tumor spreads
throughout the basal layers and the alteration of the tumor
microenvironment is responsible for the progression of the
disease (14).
Throughout time, surgery has been the main treatment
of VPD, but VPD extends beyond the clinical limits of the
lesion. In fact, the spread of Paget’s cells may be difficult

358

to recognize in a frozen section examination. This makes
margin control hard to achieve. The preferred surgical
method uses Mohs micrographic surgery to avoid falsenegative free margins in the results of the frozen section,
as in our case (15). Surgery varies from local excision to
radical vulvectomy, with a high risk of recurrence
regardless of the margin status which then leads to
increasingly mutilating surgery, and thus plastic
reconstructive surgery is often needed to cover the tissue
loss, as in our case.
Because of the mutilating surgery, a variety of other
therapeutic means have been attempted (8-10).
Radiotherapy alone or associated with chemotherapy
remains a treatment option for the relapsing disease (16,
17). But the high morbidity of those treatments has
stimulated the search for less invasive treatment options
such as chemotherapy with intralesional interferon alfa-2b,
bleomycin, laser ablation, photodynamic therapy, topical
fluorouracil (5-Fu), and imiquimod 5% cream.
The conservative treatment approach is promising
because it conserves the vulvar anatomy and the sexual
functions. Laser therapy was successfully used, but the
major disadvantages are the high rate of recurrence and the
significant pain level (18, 19).
Imiquimod 5%—an immune response modifier—is a
known treatment for vulvar condyloma, actinic keratosis,
or even basal cell carcinoma. The treatment also has a
direct antitumor activity, being first described as a local
treatment for VPD in 2003 by Wang et al. (20). A
systematic review conducted by Dogan showed the
efficacity of imiquimod as an alternative for VPD, with a
complete remission rate of 71% (21). However, treatment
protocols for imiquimod are not well codified.
Applications are generally about 3 per week, although with
widely variable durations. In our case, radiotherapy could
not be performed due to the extent of the target volumes.
Imiquimod 5% was applied twice a week for 28 weeks,
with excellent results, confirming both the efficacy and
safety of Imiquimod 5% cream in the treatment of VPD.
Another promising treatment option of VPD is topical
photodynamic therapy (PDT), with good outcomes
reported by Rioli (22), although other reports have shown
a high rate of recurrence (23). Target therapy still needs to
be approved in the treatment of VPD when HER-2/neu is
overexpressed.

Conclusions
The most challenging feature in the management of
VPD is its recurrence because the patient has undergone
increasingly mutilating surgery that leads, in some cases,
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to an impossible challenge for the surgeon. Imiquimod 5%
cream appears to be a viable alternative in such situations.
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